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MicrospongesAbstract The motive behind present work was to formulate and evaluate gel containing micro-
sponges of diclofenac diethylamine to provide prolonged release for proﬁcient arthritis therapy.
Quasi-emulsion solvent diffusion method was implied using Eudragit RS-100 and microsponges
with varied drug–polymer ratios were prepared. For the sake of optimization, diverse factors affect-
ing microparticles physical properties were too investigated. Microsponges were characterized by
SEM, DSC, FT-IR, XRPD and particle size analysis, and evaluated for morphology, drug loading,
in vitro drug release and ex vivo diffusion as well. There were no chemical interactions between drug
and polymers used as revealed by compatibility studies outcomes. The drug polymer ratio reﬂected
notable effect on drug content, encapsulation efﬁciency and particle size. SEM results revealed
spherical microsponges with porous surface, and had 7.21 lm mean particle size. The microsponges
were then incorporated in gel; which exhibited viscous modulus along with pseudoplastic behavior.
In vitro drug release results depicted that microsponges with 1:2 drug–polymer ratio were more efﬁ-
cient to give extended drug release of 75.88% at the end of 8 h; while conventional formulation get
exhausted incredibly earlier by releasing 81.11% drug at the end of 4 h only. Thus the formulated
microsponge-based gel of diclofenac diethylamine would be a promising alternative to conventional
therapy for safer and efﬁcient treatment of arthritis and musculoskeletal disorders.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diclofenac is a well recognized non-steroidal anti-in-
ﬂammatory drug (NSAID) mostly used for alleviating swelling
and pain allied with rheumatoid arthritis, juvenile rheumatoid
arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea
and other musculoskeletal ailments (Gan, 2010). Regrettably,
diclofenac oral administration has limitations such as extensive
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intramuscular injection most of the time led to skin lesions.
For these reasons, advance localized and transdermal delivery
has gained a lot of importance in these days (Niethard et al.,
2005; Kulkarni et al., 2011). Particularly, many researchers
have attempted to develop novel transdermal formulations of
diethylammonium salt of diclofenac i.e. diclofenac diethy-
lamine (DDEA) owing to its lipophilic nature and other
unique promising characteristics (Minghetti et al., 2007;
Arora and Mukherjee, 2002). Diverse approaches intended
for enhanced transdermal delivery of DDEA were incorpora-
tion in emulsion-based systems (Djordjevic et al., 2004;
Kweon et al., 2004; Vucinic-Milankovic et al., 2007), niosomal
entrapment (Manosroi et al., 2008), vehicle-chemical enhan-
cer’s implication (Djordjevic et al., 2004; Khalil et al., 2000;
Baboota et al., 2006; Zhao et al., 2009; Chaudhary et al.,
2011), lyotropic liquid–crystal encapsulation (Yariv et al.,
2010) and bicelles formation (Rubio et al., 2010), to list a few.
An efﬁcient and secure topical formulation has noteworthy
applications in treating varied disorders and clinical conditions
owing to the facts; elimination of intravenous route allied
acute toxicity, bypassing of gastrointestinal disturbances,
diminished renal toxicity, no or shorten hospitalization,
reduced dose frequency and increase patient satisfaction
(Bhanu et al., 2011; Osmani et al., 2014; Shaikh and Pawar,
2010). But conventional dermatological products typically pro-
vide actives in relatively high concentrations but for a short
duration of time; leading to a cycle of short term overmed-
ication followed by long-term under medication along with
rashes or some more serious side effects. The conventional
emulgel formulation contains isopropyl alcohol for enhancing
DDEA solubility; which is highly ﬂammable, cause cutaneous
and eye irritation and prolonged use led to dermal hyper-
sensitivity and eczema. Furthermore, gel action is terminated
swiftly as drug gets precipitated subsequent to water absorp-
tion by body tissues. So, a novel system necessitates which will
increase the presence of active agents either on skin surface or
within epidermis, concurrently reducing hasty transdermal
penetration (Bhanu et al., 2011; Bregni et al., 2008).
Microsponge-based delivery systems (MDS) give assurance
of drug localization on skin surface and within epidermis with-
out entering in systemic circulation in greater extent; thereby
reducing systemic and local cutaneous adversities. They also
offer an advantage of programmable release and are biologi-
cally safe. Additionally, this technology presents quite a lot
of beneﬁts via drug entrapment by means of better formulation
ﬂexibility, abridged side effects, improved elegance and super-
ior stability (D’souza and More, 2008; Vyas et al., 2010; Vyas
and Khar, 2002; Won, 1987).
Thus, taking into consideration the advantages of micro-
sponge drug delivery system, disadvantages of DDEA conven-
tional topical dosage forms available in market, and
non-availability of microsponge based delivery system of
DDEA in the market; present research work was aimed to
formulate and evaluate DDEA microsponge gel for its
promising effects over extended period of time.
2. Materials
Materials required for the present work were procured from
diverse sources. Diclofenac Diethylamine (DDEA) was
procured from Aarati Drugs Ltd., Mumbai, India; whileEudragit RS 100 was provided as gift sample by Evonik
Pharma, Mumbai, India. Sodium alginate and dibutyl phtha-
late were procured from Loba Chemie, Mumbai, India and
Qualigens Fine Chemicals, Mumbai, India respectively. All
the other ingredients used were of analytical grade, and were
used as procured.3. Methods
3.1. Characterization of pure drug
3.1.1. Melting point
Melting point of DDEA was noted by microcontrolled based
melting point apparatus (SMP10/1, Stuart, UK). In a capillary
tube having one end closed, sample was inserted. Then capil-
lary was inserted in bath of silicone oil which was heated in
controlled manner with the help of electric heating coil. The
temperature at which drug sample started melting was noted
as melting point temperature.
3.1.2. Differential scanning calorimetry (DSC)
To evaluate thermal behavior and thermotropic characteristics
of drug, DSC study was implied. It is based on principle of
measuring heat ﬂow in and out of sample and reference for
the period of controlled temperature cycle. Nearly 5 mg sample
was sealed in aluminum pan followed by heating at rate of
10 C/min over temperature range of 10–200 C under nitro-
gen atmosphere of ﬂow rate 10 ml/min and thermogram
(Mettler-Toledo DSC 821e, Switzerland) was obtained.
3.1.3. FTIR spectroscopy
To check purity of drug and excipients, FTIR spectra were
recorded (FTIR, A-410, Jasco, Japan) over wavelength range
of 4000–400 cm1 at resolution of 4 cm1. Samples were dis-
persed in KBr and compressed in pellets by applying 5 tons
pressure for 5 min using hydraulic press. Formed pellets were
kept in light path and spectra were recorded.
3.1.4. UV spectroscopy
Calibration curve of DDEA was plotted using phosphate buf-
fer solution (PBS) of pH 7.4 by keeping concentration range of
2–12 lg/ml. The drug was analyzed spectrophotometrically
(Pharmaspec 1700, Shimadzu, Japan) at 276 nm (regression
coefﬁcient r2 = 0.999).
3.2. Drug–excipient interaction study
Drug–excipient interactions were investigated by FTIR and
DSC studies. IR spectra were recorded to check compatibility
of drug with excipients, using FTIR spectrophotometer
(FTIR, A-410, Jasco, Japan) over wavelength range of 4000–
400 cm1 at resolution of 4 cm1. KBr dispersed samples were
compressed in pellets by applying 5 tons pressure for 5 min
using hydraulic press. Formed pellets were kept in light path
and spectra were recorded.
DSC helps in assessing the physical properties of the sample
nature (crystalline or amorphous) and indicates any probable
interaction among drug and excipients. DDEA and physical
mixture (DDEA and Eudragit RS 100) were subjected to ther-
mal analysis. Indium standard was implied for calibrating
564 R.A.M. Osmani et al.DSC enthalpy and temperature scale. Samples were kept in
aluminum pan hermetically and heated at constant rate of
10 C/min over temperature range of 10–200 C.
3.3. Preparation of DDEA microsponges
The microsponges enclosing DDEA were fabricated by quasi-
emulsion solvent diffusion method (Tansel et al., 2002; Mine
et al., 2006) using an inner phase comprising of Eudragit
RS-100 and dibutyl phthalate (1% w/v) dissolved in 5 ml of
dichloromethane. Dibutyl phthalate was added to improve
the plasticity of polymer. Further DDEA was put in and
dissolved through ultrasonication at 35 C. Followed by drop-
wise addition of this mixture into aqueous solution of sodium
alginate (outer phase) with stirring rate 500 rpm for 60 min.
Subsequently, microsponges were formed due to dichloro-
methane removal from system by evaporation. Prepared
microsponges were then ﬁltered, washed with distilled water
and subjected to drying at 40 C for 12 h in hot air oven.
Lastly microsponges obtained were weighed to determine
production yield. Various formulation batches were prepared
as per Table 1.
3.4. Evaluation of DDEA microsponges
3.4.1. Differential scanning calorimetry (DSC)
Thermogram of DDEA microsponge formulation was
obtained using differential scanning calorimeter (Mettler-
Toledo) DSC 821e outﬁtted with an intercooler. Indium
standard was implied for calibrating DSC enthalpy and tem-
perature scale. Microsponge samples were kept in aluminum
pan hermetically and heated at constant rate of 10 C/min over
temperature range of 10–200 C. By purging nitrogen with
ﬂow rate of 10 ml/min inert atmosphere was maintained.
3.4.2. Infrared spectroscopy
It was done using Fourier Transform Infrared
Spectrophotometer (FTIR A-410, Jasco, Japan) using KBr
pellet method. FTIR spectra of DDEA, Eudragit RS 100,
physical mixtures of DDEA and Eudragit RS 100, and
microsponge formulation were recorded in the wavelength
range of 4000–400 cm1.
3.4.3. Production yield
Microsponges production yield was determined by formula
mentioned below (Kilicarslan and Baykara, 2003).
Production Yield ðPYÞ¼ ½Practical Mass ofMicrosponges
=TheoroticalMassðPolymerþDrugÞ
100 ð1ÞTable 1 Composition of DDEA microsponges.
Ingredients Formulation batch
F1 F2 F
Diclofenac diethylamine: Eudragit RS 100 (mg) 1:1 1:2 1
Dichloromethane (ml) 5 5 5
Dibutyl phthalate (% w/v) 1 1 1
Sodium alginate (mg) 50 50 5
Water (ml) 100 100 13.4.4. Actual drug content and encapsulation efﬁciency
Precisely weighed quantity (100 mg) of microsponges contain-
ing drug was kept in 100 ml phosphate buffer solution (pH 7.4)
for 12 h with continuous stirring. Filtered samples (using
0.45 lmmembrane ﬁlter) were further analyzed at 276 nm next
to blank using UV spectrophotometer (Pharmaspec 1700,
Shimadzu, Japan). Estimation of drug content and encapsula-
tion efﬁciency for all batches were done using following expres-
sions (Mine et al., 2006).
Actual drug content ð%Þ ¼ ðMact=MmsÞ  100 ð2Þ
Encapsulation Efficiency ¼ ðMact=MtheÞ  100 ð3Þ
where Mact = actual DDEA content in weighed quantity of
microsponges, Mms = weighed quantity of microsponges and
Mthe = theoretical DDEA content in microsponges.
3.4.5. Scanning electron microscopy (SEM)
For assessing morphology and surface topography, prepared
microsponges were examined under scanning electron micro-
scope (LEO 440i, UK) operating at 5 kV. By means of double
adhesive tape, samples were mounted on a metal stub and
coating with platinum/palladium alloy under vacuum was
done (Nokhodchi et al., 2007).
3.4.6. Particle size analysis
Particle size analysis of prepared microsponges was carried out
using particle size analyzer (Malvern Mastersizer Hydro 2000,
Malvern, UK). Microsponges were dispersed in double dis-
tilled water before running sample in instrument to ensure that
light scattering signal (as indicated by particles count per sec-
ond) is within the sensitivity range of instrument.
3.4.7. X-ray diffraction study
X-ray diffraction patterns were recorded by using X-ray diffrac-
tometer (Siemens, Model D5000, Germany) with Cu Ka radia-
tion of wavelength 1.5405 A˚ and a crystal monochromator. The
instrument was operated at voltage 45 mV and current 20 A.
Diffraction patterns were run at 5–10 C/min in terms of 2h;
crystal and physical state of DDEA was characterized.
3.5. Preparation of gel
For preparing DDEA microsponge gel, 0.5 g of Carbopol 940
was uniformly dispersed in beakers containing sufﬁcient quan-
tity of water and was allowed to hydrate overnight. Then it
was mixed with 5 g of glycerin containing preservative to form
paste. Later 95 ml of water was added slowly to paste under
constant stirring, followed by dropwise triethanolamine addi-
tion to adjust pH to 6.5–7.5 (Maiti et al., 2011). The druges
3 F4 F5 F6 F7 F8 F9 F10
:3 1:4 1:5 1:6 1:3 1:3 1:3 1:3
5 5 5 5 5 5 5
1 1 1 1 1 1 1
0 50 50 50 30 40 60 70
00 100 100 100 100 100 100 100
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microsponges containing drug equivalent to marketed
formulation (Voltaren Emulgel 1.16% w/w).
3.6. Evaluation of DDEA microsponge gels
3.6.1. Visual inspection
The organoleptic properties such as color, texture, consistency,
homogeneity and physical appearance of gels containing
microsponges were checked by visual observation.
3.6.2. pH measurement
Diverse gel formulations pH was recorded using digital pH
meter. 5 g gel was dispersed in 45 ml distilled water at 27 C
and solution pH was measured (Purushothamrao et al.,
2010; Jain and Singh, 2010).
3.6.3. Spreadability studies
One of the requisite qualities for an ideal gel is to encompass
excellent spreadability. Spreadability is used to express extent
of area of skin or affected part to which formulation readily
spreads; which signiﬁcantly affects therapeutic efﬁcacy of
formulation. Expression of spreadability is given in terms of
time (in seconds) taken by two slides to slip off from gel placed
in between under application of speciﬁc load. Better spreadabil-
ity is indicated by minimum time required for slides separation.
Mathematical expression used for spreadability calculationwas:
S ¼ ML=T ð4Þ
whereM=weight (in g) attached to upper slide,L= length (in
cm) of glass slides, and T= time (in s) taken to separate the
slides.
Wooden block-glass slide apparatus was used and by apply-
ing weight about 20 g, time for complete separation of upper
slide (movable) from lower slide (ﬁxed) was estimated.
3.6.4. Tube extrudability
An ideal gel should possess good tube extrudability; so that when
slight pressure is applied on tube, formulation should extrude out
uniformly with an ease. Technique based upon percent quantity
of gel extruded from tube on ﬁnger pressure application was
adopted for examining extrudability.More the quantity extruded
better the extrudability. Formulations were ﬁlled in clean, lac-
quered, collapsible aluminum tubes with 5 mm nasal tip opening
and pressure was applied on tubes by means of ﬁrst ﬁnger and
thumb.Afterward tube extrudabilitywas estimated in percentage
by measuring amount of gel extruded through tip and compared
withmarketed formulation considering its extrudability as 100%
(Purushothamrao et al., 2010).
3.6.5. Viscosity measurement
The viscosity of the gel formulation was measured with a
Brookﬁeld viscometer (Capcalc V2.2) using 1x model and cone
number 01, with angular velocity of 5 rpm at 25 C. An aver-
age of ﬁve readings was used for viscosity calculation.
3.6.6. Rheological study
Rheological investigation of gel formulations was performed
using a controlled stress rheometer (Viscotech Rheometer,
Rheologica Instruments AB, Lund, Sweden). Data analysis
was done by Stress RheoLogic Basic software (version 5.0).Cone and plate geometry was used (with 25 mm diameter
and a cone angle of 1.0) operating in the oscillation and static
mode. All measurements were taken at 25 C using fresh sam-
ples every time. Relation among shear stress and shear rate
was studied by subjecting samples to increasing stress (0.1–
100 Pa). Oscillatory shear responses (G0 or elastic modulus,
and G00 or loss/viscous modulus) were also determined at low
strains over the frequency range 0.1–10 Hz. The linearity of
viscoelastic properties was veriﬁed.
3.6.7. In vitro drug release
The in vitro release of gel formulations was studied using Franz
diffusion cells. The cellophane membrane (0.45 lm) previously
soaked overnight in dissolution medium was mounted onto
Franz diffusion cell with 15 ml receptor compartment and effec-
tive diffusion area 2.84 cm2. PBS (pH 7.4) was used as receptor
medium, and system was thermostated to 37 ± 1 C under con-
stant stirring. All batches of drug microsponge gels (F1–F10)
and marketed formulation (F11) were assessed for the diffusion
study. Aliquots of 1 ml volume were withdrawn at speciﬁc time
intervals by maintaining sink condition. Withdrawn aliquots
were then diluted using receptor medium and analyzed by UV
spectrophotometer (Pharmaspec 1700, Shimadzu, Japan) at
276 nm against PBS pH 7.4. To reveal drug release mechanism
and to contrast release proﬁles disparities among formulations,
data obtained from timely drug release were used. Further,
release data were analyzed by means of diverse mathematical
models to know release kinetics (Zaki Rizkalla et al., 2011).
3.6.8. Ex vivo diffusion study
For ex vivo diffusion study by sacriﬁcingmaleWistar albino rats
(7-9 weeks old, 200-250 g) full thickness skin was excised from
abdomen, adhering subcutaneous fat was removed and were
cut into pieces just larger than the effective surface area of diffu-
sion cells. These skin pieces were immersed in normal saline
brieﬂy and then mounted between donor and receptor compart-
ments of Franz diffusion cells. The study conditions and analyti-
cal methods were identical to in vitro release study as mentioned
before (Rajan and Vasudevan, 2012). All experimental proce-
dures including handling, were approved by the Institutional
Animal Ethics Committee (Registration number: 144/2013)
complied with the guidelines set out by the Committee for the
Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Animal Welfare Division, Ministry of
Environment and Forests, Government of India, India.
3.6.9. Stability study
Optimized gel formulation was subjected to stability testing as
per ICH norms. Gel was ﬁlled in clean, lacquered, collapsible
aluminum tubes, and various replicates were kept at 40 C and
75% RH in a humidity chamber. Gel was assessed for change
in appearance, pH or in vitro release proﬁle at an interval of 7,
15, 30, 60 and 90 days.
4. Results and discussions
4.1. Characterization of pure drug
4.1.1. Melting point
Melting point of DDEA was pragmatic in range of 148–154 C
(literature standard 154 C). As experimental values were in
Figure 1 DSC thermogram of DDEA, physical mixture and
microsponge formulation.
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be pure.
4.1.2. Differential scanning calorimetry (DSC)
As reﬂected by DSC thermogram shown in Fig. 1, sharp
endothermic peak was observed at 148.54 C corresponding
to melting point of drug in crystalline form; reﬂecting drug
purity.
4.1.3. FTIR spectroscopy
FTIR spectrum of procured DDEA was recorded (Fig. 2) and
spectral interpretation was done. The characteristics IR
absorption peaks of DDEA at 419.91–859.41 cm1 (CAH
bending), 741.10 cm1 (CACl stretch), 1371.08 cm1 (CAN
stretch), 1697.49 cm1 (CAO stretch), 2882.38–2992.40 cm1
(CH2 group CAH stretch) and 3200.90 cm
1 (doublet NH
group) were there in drug sample spectrum; which conﬁrmed
the purity of DDEA.
4.2. Drug–excipient interaction study
To check out any possible interaction between drug and excipi-
ents used, compatibility study using DSC and FTIR was car-
ried out. DSC results reﬂected similar thermal behavior ofFigure 2 Overlain FTIR spectra of (a) DDEA, (b) Eudragit Rphysical mixture as that of pure drug but with quite lower
intensity. A sharp endothermic peak noted at 148.54 C in case
of DDEA, indicative of its melting point (Fig. 1). However, the
melting endotherm of microsponge formulation was sup-
pressed corresponding to partial protection of DDEA because
of microsponge encapsulation. Also, signiﬁcantly altered
crystallinity of DDEA in microsponge formulation has been
traced; conﬁrming its dispersion in the system.
FTIR spectroscopic study results discovered no any new
peak appearance or disappearance of existing peaks, discarding
any chemical interaction probability among drug and
polymer used. The characteristic ketone C‚O stretching
vibration at 1741.01 cm1, CAH bending from 416.21 to
746.42 cm1, CAO stretching at 1647.94 cm1, CACl stretch
at 746.34 cm1 and doublet NAH stretching around
3257.71 cm1 were recognized in all spectra (Fig. 2). All charac-
teristic peaks of DDEA were experiential in physical mixture
andmicrosponge formulation spectrum. Thus, IR spectroscopy
results depicted that DDEA was compatible with selected poly-
mer, excipients and possess good stability in all microsponge
formulations.
4.3. Evaluation of DDEA microsponges
4.3.1. Physical appearance
Microsponge particles with fairly white tincture were obtained
by quasi-emulsion solvent diffusion method; with good ﬂow
properties than as compared with pure drug.
4.3.2. Production yield
The production yield of all batches of microsponges ranged
from 24.55% to 79.24% (Table 2). The drug:polymer ratio
and concentration of sodium alginate was found to affect pro-
duction yield signiﬁcantly. For drug:polymer ratio 1:1 (F1),
production yield was very low i.e. 24.55% while for drug:poly-
mer ratio 1:6 (F6), it was 79.24%. It reﬂected that higher the
drug:polymer ratio, higher the productions yield. By way of
low sodium alginate concentration (30 mg, F7), production
yield was quite low i.e. 38.37% and as the concentration was
increased (from 30 mg to 70 mg) the production yield was also
found to be increased. This was due to abridged dichloro-
methane diffusion rate from concentrated solutions to aqueous
phase at higher drug:polymer concentrations; which provide
additional time for formation of droplet, thereby improving
yield.S 100, (c) physical mixture and (d) optimized formulation.
Table 2 Actual drug content, encapsulation efﬁciency and production yield.
Batch code Drug:Polymer
ratio
Theoretical drug
content (%)
Actual drug
content (%) ± SDa
Encapsulation
eﬃciency (%) ± SDa
Production
yield (%) ± SDa
F1 1:1 50 47.78 ± 0.01 95.56 ± 0.02 24.55 ± 0.26
F2 1:2 33.33 31.04 ± 0.03 93.12 ± 0.02 38.8 ± 0.23
F3 1:3 25 22.49 ± 0.01 89.96 ± 0.06 42.6 ± 0.42
F4 1:4 20 16.36 ± 0.17 81.8 ± 0.20 59.2 ± 0.01
F5 1:5 16.63 12.61 ± 0.02 75.82 ± 0.03 71.13 ± 0.08
F6 1:6 14.28 9.75 ± 0.01 68.22 ± 0.04 79.24 ± 0.02
F7 1:3 25 21.27 ± 0.01 85.08 ± 0.02 38.37 ± 0.23
F8 1:3 25 21.83 ± 0.02 87.32 ± 0.01 40.52 ± 0.12
F9 1:3 25 22.87 ± 0.01 91.48 ± 0.01 45.31 ± 0.18
F10 1:3 25 23.13 ± 0.01 92.52 ± 0.03 47.84 ± 0.16
a Standard deviation mean ‘‘n’’ = 3.
Figure 3 (a) SEM and (b) PPL microscopic images of microsponges.
Figure 4 Particle size distribution curve of microsponges.
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The mean amount of drug entrapped in fabricated micro-
sponges was found to be lesser than theoretical value for every
drug:polymer ratio employed, in view of the fact that drug
encapsulation efﬁciency did not attain 100%. This was for
the reason that some drug gets dissolved in aqueous phase or
solvent used. Encapsulation efﬁciency outcomes reﬂected that
higher drug:polymer ratios led to superior drug loadings.
Integration of higher sodium alginate amounts during micro-
sponge preparation at elevated drug:polymer ratio caused
slight increase in dispersed phase viscosity. Almost all of
dispersed phase was transformed to solid microsponges ondiffusion of solvents from inner phase, and alienated particles
emerged. The utmost drug loading efﬁciencies for these
formulations could be attributed to availability of maximum
polymer amount to apiece drug unit in contrast to rest of
formulations. The encapsulation efﬁciencies were in the range
of 68.22–95.56% as quoted in Table 2.
4.3.4. Scanning electron microscopy (SEM)
For morphology and surface topography investigation,
prepared microsponges were subjected to SEM analysis. The
captured SEM image of microsponges is shown in Fig. 3.
SEM results indicated that microsponges formed were highly
Figure 5 XRPD pattern of DDEA and microsponge
formulation.
568 R.A.M. Osmani et al.porous, predominantly spherical and not much entire DDEA
crystals were observed visually. Pores were induced by diffu-
sion of solvent from surface of microsponges. Furthermore,
it was exposed that the distinctive internal structure comprised
of spherical cavity enclosing a stiff shell assembled of drug and
polymer. The internal structure consisted of numerous
annulled spaces and appearance of particles was such that they
were perfect to term as microsponges.
Microsponges were also observed under binocular plane
polarized light (PPL) microscope (Fig. 3), which revealed that
formed microsponges were spherical as each single entity or in
form of bunches and had porous nature.
4.3.5. Particle size analysis
The average particle size of microsponge formulations should
be in the range of 5–300 lm. Visual inspection results of all
batches done using optical microscope for particle size discov-
ered increased particle size with increase in drug:polymer ratio.
It might be since polymer available at higher drug:polymer
ratio was in more amount thereby increasing polymer wall
thickness which led to larger size of microsponges. Besides,
with increasing amount of sodium alginate particle size was
found to be increased; attributed to rise in apparent viscosityFigure 6 Rheograms of oat augmented sodium alginate concentrations. It results in
the formation of bigger emulsion droplets and larger
microsponge size. Optimized batch has been found with more
percent of intact, uniform, spherical particles during optical
microscopy; hence subjected to analysis using photon correla-
tion spectroscopy (Malvern Mastersizer Hydro 2000, Malvern,
UK). The results discovered particle size corresponding to
7.215 lm (Fig. 4).
4.3.6. X-ray diffraction study
X-ray powder diffraction (XRPD) method was implied
to evaluate physicochemical characteristics of prepared
microsponges. Sharp peaks at diffraction angle (2h) 13 were
traced in X-ray diffractograms in case of both DDEA and
its microsponge formulation (Fig. 5).
For determination of occurrence of crystal habit modiﬁca-
tions and polymorphs in drug crystals, XRPD is a valuable
technique. In general when diffraction patterns are identical
for two forms of crystals, they known to posses same internal
structures and when patterns are unlike, crystals have diverse
internal structures known as polymorphs. In a study at hand,
samples depicted spectra with similar peak positions (2h
values). Consequently, no existence of polymorphs of DDEA
in these samples was veriﬁed.
Additionally, for crystallinity determination comparison of
some representative peak heights with those of a reference in
diffraction patterns has been done. Final formulation of
microsponges showed peaks at diffraction angle same as that
of XRD pattern of DDEA but with some lower intensity, indi-
cating its crystalline nature. The relative degree of crystallinity
(RDC) value was found to be 1.26. So XPRD analysis revealed
that the crystalline nature of drug was not completely lost and
was found to remain thermally stable in the ﬁnal formulation
as well.
4.4. Evaluation of DDEA microsponge gel
4.4.1. Visual inspection
The prepared gel formulations of DDEA microsponges were
inspected visually for their color, texture and appearance. All
prepared formulations were pearl white, viscous in nature with
smooth texture and of good homogeneity with no any lumps
and syneresis.ptimized formulation.
Figure 7 Comparative drug release proﬁle of F1–F10 and marketed formulation.
Table 3 Release kinetic data of microsponge formulations.
Batch code Zero order First order Higuchi Peppas Korsmeyer Peppas parameters Best ﬁt model
na ka
F1 0.964 0.940 0.994 0.991 0.6095 1.9044 Higuchi
F2 0.980 0.940 0.984 0.989 0.7108 0.9187 Peppas
F3 0.983 0.967 0.953 0.982 0.6992 0.7078 Zero
F4 0.989 0.934 0.988 0.992 0.7816 0.3993 Peppas
F5 0.981 0.899 0.992 0.990 0.7723 0.3777 Higuchi
F6 0.990 0.942 0.995 0.998 0.8926 0.3268 Peppas
F7 0.971 0.905 0.992 0.992 0.6866 0.8781 Higuchi and Peppas
F8 0.986 0.953 0.967 0.990 0.7089 0.7147 Peppas
F9 0.987 0.983 0.927 0.965 0.7115 0.6222 Zero
F10 0.979 0.972 0.949 0.976 0.7432 0.4917 Zero
a n-kinetic constant, k-release rate constant.
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The pH values of all prepared formulations were found in the
range of 6.5–6.8, which are supposed to be suitable to pass up
threat of nuisance on application to skin.
4.4.3. Spreadability study
The ﬁndings of spreadability depicted that formulated gels get
easily spread on applying small amount of shear. Spreadability
of gel containing unentrapped drug was found to be 3.52 g cm/s;
while that of microsponge formulation it was 4.18 g cm/s;
indicating that spreadability of drug loaded microsponge gel
was good as compared to that of marketed one.
4.4.4. Extrudability study
The extrudability of prepared microsponge gel was found to be
96.63% when calculated by considering extrudability ofunentrapped drug gel as 100%. Accordingly, the prepared
formulation exhibited better extrudability which is one of the
ideal characteristics.4.4.5. Viscosity and rheological study
The viscosity of prepared DDEA microsponge gel was found
to be 42,300 cPs. To investigate viscoelastic properties, rheo-
logical analysis of optimized gel formulation was done. It
has been found that for gel system, viscous modulus (G00)
was higher than elastic modulus (G0) indicating that the system
was viscous. The formulation showed pseudoplastic rheology
as evident by shear thinning and a decrease in viscosity with
an increase in shear stress. The curved rheograms were resul-
tant to shearing action onto long chain polymer molecules
(Fig. 6). As shearing stress was raised, normally disarranged
molecules start to line up their long axes in direction of ﬂow.
Figure 8 Drug diffusion proﬁles of F1–F10 formulations.
Table 4 Effect of composition of external phase.
Batch code Sodium alginate concentration (mg) Production yield (%) ± SDa Encapsulation eﬃciency (%) ± SDa % CDR± SDa
F7 30 38.37 ± 0.23 85.08 ± 0.02 62.51 ± 0.76
F8 40 40.52 ± 0.12 87.32 ± 0.01 61.08 ± 0.59
F3 50 42.6 ± 0.42 89.96 ± 0.06 59.12 ± 0.53
F9 60 45.31 ± 0.18 91.48 ± 0.01 57.81 ± 0.57
F10 70 47.84 ± 0.16 92.52 ± 0.03 54.26 ± 0.62
a Standard deviation mean ‘‘n’’ = 3.
Table 5 Effect of drug–polymer ratio.
Batches Drug:polymer
ratio
Production yield
(%) ± SDa
Drug content
(%) ± SDa
Encapsulation eﬃciency
(%) ± SDa
%
CDR± SDa
Flux
(mg/cm2 h)
F1 1:1 24.55 ± 0.26 47.78 ± 0.01 95.56 ± 0.02 84.18 ± 0.01 0.3181
F2 1:2 38.8 ± 0.23 31.04 ± 0.03 93.12 ± 0.02 75.88 ± 0.03 0.2968
F3 1:3 42.6 ± 0.42 22.49 ± 0.01 89.96 ± 0.06 59.12 ± 0.02 0.2207
F4 1:4 59.2 ± 0.01 16.36 ± 0.17 81.8 ± 0.20 50.27 ± 0.05 0.1999
F5 1:5 71.13 ± 0.08 12.61 ± 0.02 75.82 ± 0.03 43.66 ± 0.01 0.1742
F6 1:6 79.24 ± 0.02 9.75 ± 0.01 68.22 ± 0.04 40.69 ± 0.01 0.1621
a Standard deviation mean ‘‘n’’ = 3.
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permitted better shear rate on every consecutive shearing
stress. The viscosity was found to be reliant on polymeric con-
tent of formulation.
4.4.6. In vitro drug release
The drug release was observed to decline within range of
84.18–40.69% with respect to rise in drug:polymer ratio from
1:1 to 1:6. The reason behind is as drug:polymer ratio has
increased; in each microsponge, to encapsulate drug, the poly-
mer amount available was more. It led to thickening of poly-
mer matrix wall, thus extended diffusion path and ultimately
lesser drug release. The highest drug release i.e. 84.18% was
found for the formulation F1, while the lowest 40.69% for
F6. Initial burst release observed in case of formulations F1
and F2 can be allocated to existence of non-encapsulated drug
near surface or on the exterior of microsponges. Graphical pre-
sentation for comparative drug release of all batches F1–F6
and F7–F10 is shown in Fig. 7.
It has been reported that with increasing amount of sodium
alginate from batches F7 to F10, the drug release went on
decreasing. It might be due to fact that the polymer matrix
releases drug after complete swelling and the time requiredfor swelling of polymer is directly proportional to stabilizer
concentration. The declined release rate with increased amount
of sodium alginate for formulations F7–F10 was from 62.51%
to 54.26%.
4.4.7. Release proﬁle of unentrapped DDEA gel
Drug release study for gel containing unentrapped DDEA i.e.
marketed formulation (VoltarenEmulgel 1.16%w/w) was car-
ried out, release proﬁle of which was as depicted in Fig. 7. The
gel got exhausted by releasing 81.11% of drug at the end of 4 h
only. In contrast microsponge-based gel exhibited sustained
drug release up to 8 h thereby minimizing the side effects, skin
irritation and hypersensitivity reactions. As the F2 formulation
exhibited 75.88% drug release after completion of 8 h, and also
found superior in terms of percent intact porous microsponges,
other physical parameters and drug release. So, F2 formulation
has been considered as best and more efﬁcient to give an
extended drug release among the all.
4.4.8. Drug release kinetics
The in vitro release data were subjected to various release mod-
els namely, zero order, ﬁrst order, Higuchi, Peppas and
Korsmeyer–Peppas, and by highest r2 value best ﬁt model
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sion value for the Peppas model (0.998 for F6). Peppas model
was found to be best ﬁt for most of the formulations, on the
basis of maximum regression values (Table 3). By putting
release data in Korsmeyer equation drug release mechanism
for all formulations was investigated. For formulations
F1–F10, n values were found in range 0.6095–0.8926. The n
value for Korsmeyer–Peppas model was seen to be in the range
0.5–1, which is indicative of non-Fickian diffusion.
4.4.9. Ex vivo diffusion study
The ex vivo diffusion studies were completed for all formula-
tions on excised rat skin with use of PBS (pH 7.4). It has been
observed that the formulation F1 exhibited higher drug
diffusion on completion of 8 h while that of F6 it was contra-
dictory. Similarly in case of formulations F7–F10, there was a
slight decrease in amount of drug diffused from F7 to F10
respectively. Study results indicated that the Q value (collective
sum of drug permeated per unit surface area of skin) was
decreased at higher ratio due to an increase in Eudragit RS
100 concentration, and also it was found to decrease at high
sodium alginate concentrations. The cumulative amount of
drug diffused per unit surface area of skin (CADD) from
microsponge containing gel formulations was plotted against
time as shown in Fig. 8. The slopes of linear portions of
obtained permeation proﬁles were estimated as steady state
ﬂux (J) of drug from gel formulations. As compared to
F1–F3 the ﬂux of drug was found to be relatively sluggish
for batches F4–F6; reﬂecting slow discharge of entrapped drug
from these microsponges. The sum of drug permeated through
unit area subsequent to 8 h was also found to be lower for
batches F4–F6.
The drug diffusion rate for ﬁrst 1 h was found to be
elevated compare to next 7 h in case of all formulations. This
was possibly being attributable to the release of free unen-
trapped DDEA which affected the ﬂux at ﬁrst that goes slowly
decreased for the next 7 h. Thus, retarded release of entrapped
drug from microsponges was established by slower ﬂux values.
4.4.10. Effect of formulation variables
4.4.10.1. Effect of composition of external phase. Composition
of external phase was altered for formulations F7–F10 by
changing concentration of sodium alginate from 30 to 70 mg.
It has been observed that on increasing the amount of sodium
alginate, production yield, encapsulation efﬁciency andFigure 9 Drug release proﬁle of microsponge gel during stability
study.particle size were increased while slight decrease in drug release
was noticed (Table 4).
4.4.10.2. Effect of drug:polymer ratio. Increase in drug:polymer
ratio has been found to result as increase in production yield;
while drug content, encapsulation efﬁciency and percent drug
release were found to be decreased (Table 5). The reason
behind that is as drug:polymer ratio went on increasing, the
polymer amount available for each microsponge to encapsu-
late the drug was more, thus rising polymer matrix wall thick-
ness which led to extended diffusion path and ultimately to
lesser drug release. Consequently the amount of drug diffused
and ﬂux of the formulations were decreased at higher
drug:polymer ratio.
4.4.11. Stability study
During stability studies formulation appearance was found
pearl white, homogenous, smooth and no signiﬁcant deviation
in pH was seen. It was also noted from outcomes that there
were no considerable changes in drug content as well as per-
cent drug release. Therefore no evidence of degradation of
drug was observed.
After comparative assessment of optimized formulation
(F2) drug release proﬁles prior and after 3 months stability
study, similarity factor (f2) was calculated (Fig. 9). Similarity
factor was found to be f2 = 82.38 (>50). As similarity factor
greater than 50 indicates good stability of the product, in view
of this it has been concluded that the formulation was stable
over the period of 3 months.
5. Conclusions
Controlled drug delivery via the polymer based systems has
been proposed to be prevailing both in present and in future;
as having numerous potential advantages for scientiﬁc as well
as economic reasons. The thought behind developing poly-
meric microsponge delivery system was to deliver DDEA in
a continual manner for extensive time period to reduce appli-
cation frequency, hypersensitive reactions and to improve
bioavailability, safety than marketed conventional formula-
tion. The method implemented was quasi-emulsion solvent dif-
fusion; found to be simple, reproducible and rapid. Formed
microsponges were spherical shape, have high porosity and
good ﬂow. Varied drug–polymer ratio reﬂected remarkable
effect on particle size, drug content and encapsulation efﬁ-
ciency. Microsponge-based gel showed viscous modulus along
with pseudoplastic behavior and in vitro drug release reﬂected
highest regression value for Peppas model. Formulation with
1:2 drug–polymer ratio was found more efﬁcient to give
extended drug release (75.88% at 8 h); while conventional
formulation exhausted extremely earlier (81.11% at 4 h).
Thus, gel containing microsponges prepared in this study
was found to be promising as new-fangled delivery system
offering prolonged release of DDEA in treating rheumatoid
arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylos-
ing spondylitis and other musculoskeletal ailments.Acknowledgments
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